Profound Regulatory Friday, July 24, 2026 +0.75 Positive

TULSA ablation preserves penile length vs. robotic prostate surgery

Profound Medical announced data from its CAPTAIN trial where the TULSA Procedure demonstrated statistically significant superior penile length preservation compared to robotic radical prostatectomy, showing no median change versus a 0.65 cm loss.

View original filing at SEC.gov →
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

GET FREE KEY — 10,000 calls/day